Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: Biomarkers or mediators

Clinica Chimica Acta

Volumn 443, Issue , 2015, Pages 3-8

  Buglioni, Alessia ^a   Burnett, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Biomarkers; Cardiorenal axis; Heart failure; Mediators; Natriuretic peptides; RAAS

Indexed keywords

ADRENALIN; ADRENOMEDULLIN; ALDOSTERONE; ANGIOTENSIN II; ENDOTHELIN; GALECTIN 3; HYDROCORTISONE; INTERLEUKIN 1; INTERLEUKIN 6; NATRIURETIC FACTOR; NEUROHORMONE; NORADRENALIN; PARATHYROID HORMONE; RENIN; TROPONIN; TUMOR NECROSIS FACTOR ALPHA; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BIOLOGICAL MARKER;

AMINO TERMINAL SEQUENCE; ARTICLE; CARDIORENAL SYNDROME; CARDIOVASCULAR MORTALITY; ENDOCRINE DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HORMONE ACTION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BLOOD; CARDIO-RENAL SYNDROME; HEART STROKE VOLUME; PATHOPHYSIOLOGY;

BIOMARKERS; CARDIO-RENAL SYNDROME; HEART FAILURE; HUMANS; NEUROTRANSMITTER AGENTS; STROKE VOLUME;

EID: 84924239991     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.10.027     Document Type: Article

References (67)

1. Jessup M., Brozena S. Heart failure. N Engl J Med 2003, 348:2007-2018.
2. Gheorghiade M., Zannad F., Sopko G., Klein L., Pina I.L., Konstam M.A., et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005, 112:3958-3968.
3. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013, 128:e240-e327.
4. van Heerebeek L., Borbely A., Niessen H.W., Bronzwaer J.G., van der Velden J., Stienen G.J., et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006, 113:1966-1973.
5. Braunwald E. Heart failure. JACC Heart Fail 2013, 1:1-20.
6. Lam C.S., Donal E., Kraigher-Krainer E., Vasan R.S. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011, 13:18-28.
7. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
8. Komajda M., Lam C.S. Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J 2014, 35:1022-1032.
9. Redfield M.M. Understanding "diastolic" heart failure. N Engl J Med 2004, 350:1930-1931.
10. Borlaug B.A., Redfield M.M. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 2011, 123:2006-2013. [discussion 14].
11. Little W.C., Zile M.R. HFpEF: cardiovascular abnormalities not just comorbidities. Circ Heart Fail 2012, 5:669-671.
12. Solomon S.D., Zile M., Pieske B., Voors A., Shah A., Kraigher-Krainer E., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012, 380:1387-1395.
13. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013, 15:1062-1073.
14. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014, 371:993-1004.
15. Jessup M. Neprilysin inhibition-a novel therapy for heart failure. N Engl J Med 2014, 371:1062-1064.
16. Pitt B., Pfeffer M.A., Assmann S.F., Boineau R., Anand I.S., Claggett B., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014, 370:1383-1392.
17. McMurray J.J., O'Connor C. Lessons from the TOPCAT trial. N Engl J Med 2014, 370:1453-1454.
18. Burnett J.C., Kao P.C., Hu D.C., Heser D.W., Heublein D., Granger J.P., et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986, 231:1145-1147.
19. Triposkiadis F., Karayannis G., Giamouzis G., Skoularigis J., Louridas G., Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009, 54:1747-1762.
20. Becker J.R., Chatterjee S., Robinson T.Y., Bennett J.S., Panakova D., Galindo C.L., et al. Differential activation of natriuretic peptide receptors modulates cardiomyocyte proliferation during development. Development 2014, 141:335-345.
21. Sangaralingham S.J., Huntley B.K., Martin F.L., McKie P.M., Bellavia D., Ichiki T., et al. The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic peptide. Hypertension 2011, 57:201-207.
22. Moro M.A., Russel R.J., Cellek S., Lizasoain I., Su Y., Darley-Usmar V.M., et al. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A 1996, 93:1480-1485.
23. Greene S.J., Gheorghiade M., Borlaug B.A., Pieske B., Vaduganathan M., Burnett J.C., et al. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc 2013, 2:e000536.
24. Burnett J.C., Opgenorth T.J., Granger J.P. The renal action of atrial natriuretic peptide during control of glomerular filtration. Kidney Int 1986, 30:16-19.
25. Richards A.M. The renin-angiotensin-aldosterone system and the cardiac natriuretic peptides. Heart 1996, 76:36-44.
26. Melo L.G., Veress A.T., Ackermann U., Sonnenberg H. Chronic regulation of arterial blood pressure by ANP: role of endogenous vasoactive endothelial factors. Am J Physiol 1998, 275:H1826-H1833.
27. Eiserich J.P., Hristova M., Cross C.E., Jones A.D., Freeman B.A., Halliwell B., et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998, 391:393-397.
28. Liu V.W., Huang P.L. Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc Res 2008, 77:19-29.
29. Wilkinson I.B., Franklin S.S., Cockcroft J.R. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension 2004, 44:112-116.
30. Bhushan S., Kondo K., Polhemus D.J., Otsuka H., Nicholson C.K., Tao Y.X., et al. Nitrite therapy improves left ventricular function during heart failure via restoration of nitric oxide-mediated cytoprotective signaling. Circ Res 2014, 114:1281-1291.
31. Jackson G., Gibbs C.R., Davies M.K., Lip G.Y. ABC of heart failure. Pathophysiology. BMJ 2000, 320:167-170.
32. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med 2001, 345:1689-1697.
33. von Lueder T.G., Sangaralingham S.J., Wang B.H., Kompa A.R., Atar D., Burnett J.C., et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail 2013, 6:594-605.
34. Beygui F., Vicaut E., Ecollan P., Machecourt J., Van Belle E., Zannad F., et al. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am Heart J 2010, 160:642-648.
35. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
36. Pitt B., White H., Nicolau J., Martinez F., Gheorghiade M., Aschermann M., et al. Eplerenone reduces mortality 30days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005, 46:425-431.
37. Vigliano C.A., Cabeza Meckert P.M., Diez M., Favaloro L.E., Cortes C., Fazzi L., et al. Cardiomyocyte hypertrophy, oncosis, and autophagic vacuolization predict mortality in idiopathic dilated cardiomyopathy with advanced heart failure. J Am Coll Cardiol 2011, 57:1523-1531.
38. Ronco C., Haapio M., House A.A., Anavekar N., Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008, 52:1527-1539.
39. Metra M., Cotter G., Gheorghiade M., Dei Cas L., Voors A.A. The role of the kidney in heart failure. Eur Heart J 2012, 33:2135-2142.
40. Bock J.S., Gottlieb S.S. Cardiorenal syndrome: new perspectives. Circulation 2010, 121:2592-2600.
41. Burnett J.C., Knox F.G. Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol 1980, 238:F279-F282.
42. Gori M., Senni M., Gupta D.K., Charytan D.M., Kraigher-Krainer E., Pieske B., et al. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J 2014.
43. Dries D.L., Exner D.V., Domanski M.J., Greenberg B., Stevenson L.W. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000, 35:681-689.
44. Fried L.F., Shlipak M.G., Crump C., Kronmal R.A., Bleyer A.J., Gottdiener J.S., et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003, 41:1364-1372.
45. Martin F.L., McKie P.M., Cataliotti A., Sangaralingham S.J., Korinek J., Huntley B.K., et al. Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Am J Physiol Regul Integr Comp Physiol 2012, 302:R292-R299.
46. Anand I.S. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003, 107:1278-1283.
47. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
48. Finley JJt, Konstam M.A., Udelson J.E. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 2008, 118:410-421.
49. Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsuo H., et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993, 192:553-560.
50. Yu C.M., Cheung B.M., Leung R., Wang Q., Lai W.H., Lau C.P. Increase in plasma adrenomedullin in patients with heart failure characterised by diastolic dysfunction. Heart 2001, 86:155-160.
51. Whitworth J.A., Mangos G.J., Kelly J.J. Cushing, cortisol, and cardiovascular disease. Hypertension 2000, 36:912-916.
52. Funder J.W. Minireview: aldosterone and mineralocorticoid receptors: past, present, and future. Endocrinology 2010, 151:5098-5102.
53. Anand I.S., Ferrari R., Kalra G.S., Wahi P.L., Poole-Wilson P.A., Harris P.C. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989, 80:299-305.
54. Lerman A., Sandok E.K., Hildebrand F.L., Burnett J.C. Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction. Circulation 1992, 85:1894-1898.
55. Kiowski W., Stsch G., Hunziker P., Mller P., Jonghun K., Oechslin E., et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995, 346:732-736.
56. Anker S.D. Inflammatory mediators in chronic heart failure: an overview. Heart 2004, 90:464-470.
57. Iraqi W., Rossignol P., Angioi M., Fay R., Nuee J., Ketelslegers J.M., et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009, 119:2471-2479.
58. Ky B., French B., McCloskey K., Rame J.E., McIntosh E., Shahi P., et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011, 4:180-187.
59. Chen W.C., Tran K.D., Maisel A.S. Biomarkers in heart failure. Heart 2010, 96:314-320.
60. Felker G.M., Fiuzat M., Thompson V., Shaw L.K., Neely M.L., Adams K.F., et al. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circ Heart Fail 2013, 6:1172-1179.
61. Sharma U.C., Pokharel S., van Brakel T.J., van Berlo J.H., Cleutjens J.P., Schroen B., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121-3128.
62. Gruson D., Buglioni A., Burnett J.C. PTH: potential role in management of heart failure. Clin Chim Acta 2014, 433:290-296.
63. Gruson D., Lepoutre T., Ketelslegers J.M., Cumps J., Ahn S.A., Rousseau M.F. C-terminal FGF23 is a strong predictor of survival in systolic heart failure. Peptides 2012, 37:258-262.
64. Bozkurt B. Use of biomarkers in the management of heart failure: are we there yet?. Circulation 2003, 107:1231-1233.
65. Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008, 7:827-840.
66. Eschalier R., Rossignol P., Kearney-Schwartz A., Adamopoulos C., Karatzidou K., Fay R., et al. Features of cardiac remodeling, associated with blood pressure and fibrosis biomarkers, are frequent in subjects with abdominal obesity. Hypertension 2014, 63:740-746.
67. Eschalier R., Fertin M., Fay R., Bauters C., Zannad F., Pinet F., et al. Extracellular matrix turnover biomarkers predict long-term left ventricular remodeling after myocardial infarction: insights from the REVE-2 study. Circ Heart Fail 2013, 6:1199-1205.